R&D productivity rides again?

Dennis Lendrem*, Stephen J. Senn, B. Clare Lendrem, John D. Isaacs

*Corresponding author for this work

    Research output: Contribution to journalArticleResearchpeer-review

    19 Citations (Scopus)


    A recent analysis of R&D productivity suggests that there are grounds for 'cautious optimism' that the industry 'turned the corner' in 2008 and is 'on the comeback trail'.We believe that this analysis is flawed and most probably wrong.We present an alternative analysis of these same data to suggest that the industry is not yet 'out of the woods' and suggest that many of the systemic issues affecting pharmaceutical R&D productivity are still being resolved.

    Original languageEnglish
    Pages (from-to)1-3
    Number of pages3
    JournalPharmaceutical Statistics
    Issue number1
    Publication statusPublished - 1 Jan 2015


    • Costs
    • Development
    • Pharmaceutical industry
    • Pharmaceutical innovation crisis
    • R&D costs
    • R&D productivity
    • Strategy


    Dive into the research topics of 'R&D productivity rides again?'. Together they form a unique fingerprint.

    Cite this